pembrolizumab,lenvatinib
merck,eisai
['key,note,b61', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'keynoteb61', 'lenva']
is len-pem best performer in nccrcc? results of ph2 keynoteb61 evaluating lenvatinib+pembrolizumab in #nccrcc:
-158 patients w/ nccrcc
-orr 49%
-mpfs 17.9m
-os pending
-mdor nr, 75% of responders w/ response &gt;/12m #asco23 
Medical oncologist @GACancerCenter, Augusta University specializing in genitourinary &breast oncology. Editor and TB moderator @themednet.org #patientadvocate